- Home
- BMRN vs MDGL Comparison
BMRN vs MDGL Comparison
Compare BMRN & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMRN | MDGL |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 11.5B |
| IPO Year | 1999 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BMRN | MDGL |
|---|---|---|
| Price | $56.34 | $468.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 19 |
| Target Price | $91.59 | ★ $685.78 |
| AVG Volume (30 Days) | ★ 2.1M | 249.5K |
| Earning Date | 10-30-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $1,313,646,000.00 | $180,133,000.00 |
| Revenue This Year | $21.42 | $59.57 |
| Revenue Next Year | $14.51 | $38.84 |
| P/E Ratio | $70.97 | ★ N/A |
| Revenue Growth | ★ 17.62 | N/A |
| 52 Week Low | $49.26 | $393.61 |
| 52 Week High | $70.98 | $615.00 |
Technical Indicators
Market Signals| Indicator | BMRN | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 23.85 |
| Support Level | $53.61 | $416.21 |
| Resistance Level | $57.95 | $546.29 |
| Average True Range (ATR) | 1.42 | 16.04 |
| MACD | -0.06 | -4.04 |
| Stochastic Oscillator | 11.06 | 4.39 |
Price Performance
Historical ComparisonAbout BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.